Detalhe da pesquisa
1.
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Invest New Drugs
; 41(2): 267-275, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36792805
2.
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
JNCI Cancer Spectr
; 8(3)2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38627238